Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease

Table 1

Glycaemic control and renoprotection in studies of SGLT2 inhibition in subjects with moderate chronic kidney disease.

Study 1 [7]	Placebo	Dapagliflozin 5 mg	Dapagliflozin 10 mg
HbA1c^*
Baseline, %	8.5	8.3	8.2
Changes at week 24, %	−0.28	−0.38	−0.41
Changes at week 104, %	−0.67	−1.21	−0.75
GFR
Baseline, mL/min/1.73 m^2	45.6	44.2	43.9
Changes at week 24, mL/min/1.73 m^2	−0.3	−2.4	−4.8
Changes at week 104, mL/min/1.73 m^2	−2.4	−1.7	−3.5
Study 2 [8, 9]	Placebo	Canagliflozin 100 mg	Canagliflozin 300 mg
HbA1c
Baseline, %	8.0	7.9	8.0
Changes at week 26, %	−0.03	−0.33	−0.44
Changes at week 52, %	−0.07	−0.19	−0.33
GFR
Baseline, mL/min/1.73 m^2	40.1	39.7	38.5
Changes at week 26, mL/min/1.73 m^2	−1.8	−3.6	−3.9
Changes at week 52, mL/min/1.73 m^2	−1.6	−2.1	−4.0
Urinary albumin/creatinine ratio
Baseline, g/mg	31.3	23.7	30.1
Changes at week 26, %	−7.5	−29.9	−20.9
Changes at week 52, %	19.7	−16.4	−28.0
Study 3 [10]	Placebo	Empagliflozin 25 mg
HbA1c
Baseline, %	8.0	8.0
Changes at week 24, %	0.05	−0.37

No statistically significant change in hemoglobin A1c (HbA1c).